Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952004 | 0.87 | TSHR (0.41) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL6216932 | 0.87 | TSHR (0.41) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL15614299 | 0.85 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL320584 | 0.85 | ALDH1A1 (0.61) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL1527132 | 0.85 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL23522296 | 0.82 | GABRA1 (0.42) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL4183355 | 0.82 | ERN1 (0.44) | CA1CA2CYP1A2CYP3A4KMT2A | |
| SCHEMBL6214960 | 0.80 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL954358 | 0.78 | TSHR (0.50) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL677075 | 0.77 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-11611046-B2 | Organic electroluminescent device | MERCK PATENT GMBH (DE) | 2023-03-21 | — | — | US | disclosed |
| WO-2020217229-A1 | POLYCYCLIC COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND OR THE COMPOSITION | IDEMITSU KOSAN CO., LTD. (JP) | 2020-10-29 | — | — | WO | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| CN-105593235-B | The production method of group with imine moiety, catalyst for olefines polymerizing and olefin polymer | 日本聚丙烯株式会社 | 2018-04-10 | — | — | CN | disclosed |
| US-9862783-B2 | Imine compound, novel catalyst for olefin polymerization, and process for producing olefin polymer | JAPAN POLYPROPYLENE CORPORATION (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9862783-B2 | Imine compound, novel catalyst for olefin polymerization, and process for producing olefin polymer | JAPAN POLYPROPYLENE CORPORATION (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20170077418-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20160237184-A1 | IMINE COMPOUND, NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER | JAPAN POLYPROPYLENE CORPORATION (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20040214970-A1 | Imidochromium compounds in catalyst systems for olefin polymerization | EQUISTAR CHEMICALS, LP | 2004-10-28 | — | — | US | disclosed |
| US-6784261-B1 | OBTAINED BY A PROCESS ENCOMPASSING THE FOLLOWING PROCESS STEPS: CONTACTING A DIOXOCHROMIUM COMPOUND WITH AN N-SULFINYL COMPOUND, CONTACTING THE REACTION PRODUCT THUS OBTAINED WITH CHLORINE, AT LEAST ONE ACTIVATOR COMPOUND | BASELL POLYOLEFINE GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| CN-1145623-C | Imidazole derivatives | - | 2004-04-14 | — | — | CN | disclosed |
| EP-0797575-B1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | disclosed |
| EP-1200453-B1 | IMIDOCHROME COMPOUNDS CONTAINED IN CATALYST SYSTEMS FOR OLEFIN POLYMERISATION | BASELL POLYOLEFINE GMBH (DE) | 2003-02-19 | — | — | EP | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| US-5959113-A | REACTING A DIKETONE DERIVATIVE WITH AN ALDEHYDE DERIVATIVE; ADMINISTERING TO TREAT ATHEROSCLEROSIS, PSORIASIS, ALOPECIA AND TUMORS | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1175252-A | Imidazole derivatives as protein kinase inhibitors in particular egf-rthyrosine kinase | HOFFMANN LA ROCHE (CH) | 1998-03-04 | — | — | CN | disclosed |
| EP-0797575-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018626-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214970-A1 | Imidochromium compounds in catalyst systems for olefin polymerization | HCCS, PPOX, INF2 | GABRA1 3668/4885GABRG2 4187/4885GABRB3 3397/4885 |
| US-20170077418-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | EPCAM, L1CAM, LAGE3 | GABRA1 2129/4885GABRG2 1792/4885GABRB3 1979/4885 |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | GABRA1 601/4885GABRG2 1032/4885GABRB3 484/4885 |
| US-20160237184-A1 | IMINE COMPOUND, NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER | ODC1, MACF1, MOGAT2 | GABRA1 4009/4885GABRG2 4334/4885GABRB3 4210/4885 |
| US-11611046-B2 | Organic electroluminescent device | EPCAM, L1CAM, LAGE3 | GABRA1 2129/4885GABRG2 1792/4885GABRB3 1979/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | GABRA1 601/4885GABRG2 1032/4885GABRB3 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.